OCV-C01

peptide cocktail vaccine containing epitope peptides derived from KIF20A, vascular endothelial growth factor receptor (VEGFR)1 and VEGFR2 combined with gemcitabine in the adjuvant treatment for resected pancreatic cancer patients

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Hirono, Seiko: 1 article (01/2017)
2.	Imaoka, Hiroshi: 1 article (01/2017)
3.	Ishii, Hiroshi: 1 article (01/2017)
4.	Katanuma, Akio: 1 article (01/2017)
5.	Katsuda, Masahiro: 1 article (01/2017)
6.	Kawai, Manabu: 1 article (01/2017)
7.	Maguchi, Hiroyuki: 1 article (01/2017)
8.	Miyazawa, Motoki: 1 article (01/2017)
9.	Okada, Ken-Ichi: 1 article (01/2017)
10.	Ozaka, Masato: 1 article (01/2017)

Related Diseases

1.

Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2017 - "OCV-C01 combined with gemcitabine was tolerable with a median DFS of 15.8 months, which was favorable compared with previous data for resected pancreatic cancer." 01/01/2017 - "We investigated peptide cocktail vaccine OCV-C01 containing epitope peptides derived from KIF20A, vascular endothelial growth factor receptor (VEGFR)1 and VEGFR2 combined with gemcitabine in the adjuvant treatment for resected pancreatic cancer patients. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
2.	Vaccines
3.	Peptides (Polypeptides)
4.	Epitopes
5.	Gemcitabine